Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial

BACKGROUND: The phase III JACOB trial (NCT01774786) compared the efficacy and safety of pertuzumab and trastuzumab plus chemotherapy with placebo and trastuzumab plus chemotherapy in patients with previously untreated human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric or gas...

Descripción completa

Detalles Bibliográficos
Autores principales: Shitara, Kohei, Hara, Hiroki, Yoshikawa, Takaki, Fujitani, Kazumasa, Nishina, Tomohiro, Hosokawa, Ayumu, Asakawa, Takashi, Kawakami, Satoe, Muro, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989577/
https://www.ncbi.nlm.nih.gov/pubmed/31620931
http://dx.doi.org/10.1007/s10147-019-01558-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989577/
https://www.ncbi.nlm.nih.gov/pubmed/31620931
http://dx.doi.org/10.1007/s10147-019-01558-z

Ejemplares similares